Latanoprost PH&T receives Marketing Authorisation in Germany, Greece, Ireland, Poland and the United Kingdom.

April 2011 Latanoprost PH&T is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma and ocular hypertension..

Latanoprost PH&T is also indicated for the reduction of elevated intraocular pressure in paediatric patients with elevated intraocular pressure and paediatric glaucoma.

Primary open-angle glaucoma is a major health concern throughout the world because of its usually silent, progressive nature and because it is one of the leading preventable causes of blindness in the world. With appropriate screening and treatment by an ophthalmologist glaucoma can usually be identified and stopped before significant vision loss occurs.

Worldwide, studies found the following:
More than 3 million people are blind in both eyes from primary open-angle glaucoma.
More than 2 million people will develop primary open-angle glaucoma each year.